Welcome to the Working Group on New TB Drugs Blog

An Interview with Bill R. Jacobs, Jr., Ph.D
Spotlight: Dr. Michele Miller on TB in Wildlife – Part Two

TB R&D Spotlight Interview with Dr. Michele Miller: In part two of our interview, we discuss the impact that TB could have on wildlife populations. Tuberculosis is currently a leading infectious disease in both human and animal populations across the world. Because it is an older disease, it goes under recognized in all groups â especially wildlife. While it may not generate as much attention as HIV, or Ebola, it can have greater impact on the balance of the environment and our wildlife populations.
Interview with Gyanu Lamicchane
Spotlight: Dr. Michele Miller on TB in Wildlife – Part One

TB R&D Spotlight Interview with Dr. Michele Miller: When we think of infectious diseases, such as HIV or Tuberculosis, we usually consider them to be a human problem â there are rarely reports of disease in animals, unless it impacts people directly. The reality, however, is that infection greatly impacts domestic and wild animals, greatly affecting the health of our environment.
Interview with Joel S. Freundlich
An Interview with Dr. Dennis Mitchison: Part Three of a Three Part Series

This is the last from the series of three. When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. For more than half a century, Dr. Mitchison has been dedicated to discovering new treatments for tuberculosis. Recently, we had the privilege to chat with Dr. Mitchison to learn more about his life and get his views on tuberculosis and the state of research and development for new TB drugs.
From HIV to Tuberculosis and Back Again: A Tale of Activism in 2 Pandemics

This article originally appeared in Clinical Infectious Diseases 2010;50:S260âS266.
Tuberculosis (TB) and human immunodeficiency virus (HIV) infections are the deadliest chronic infections globally. Although each is deadly alone, they are deadlier together, with TB causing oneâquarter of AIDSârelated deaths and HIV infecting at least 15% of patients with TB worldwide.
An Interview with Dr. Dennis Mitchison: Part Two of a Three Part Series

This is part 2 in a series. When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. For more than half a century, Dr. Mitchison has been dedicated to discovering new treatments for tuberculosis. Recently, we had the privilege to chat with Dr. Mitchison to learn more about his life and get his views on tuberculosis and the state of research and development for new TB drugs.
In memoriam: Dr. Karel De Beule
An Interview with Dr. Dennis Mitchison: Part One of a Three Part Series

When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. Born on September 6, 1916, Dr. Mitchison has had a long career dedicated to treating tuberculosis. After qualifying in Medicine from University College in 1943, he began his career in Pathology at the Brompton Hospital at the time that the first clinical trial with a randomised intake between treatment of pulmonary tuberculosis with streptomucin or with bed rest alone was run.









